Shoreline Medical Administration, CHUM Health and Cellution Biologics Launch Elite Graft Program for Advanced Wound CareNew collaborative program brings together an industry leading biologic graft, wound care specific revenue cycle management and the only clawback protection program in one coordinated solution
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.Acquisition expands Cellution Biologics’ human tissue-based portfolio and marks its entry into the U.S. reconstructive surgery market
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft PortfolioROSWELL, Ga., July 16, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc., a biologics company focused on developing, manufacturing, and commercializing advanced human tissue-based products for wound care, ocular repair, and other surgical applications, today announced that it has signed a definitive agreement to acquire the SimpliDerm® hydrated human acellular dermal matrix ("ADM") business from Elutia Inc.
Cellution Biologics Celebrates Expansion of U.S. Headquarters in Roswell, GeorgiaRibbon Cutting Ceremony to Mark Continued Growth and Investment in U.S. Operations
Cellution Biologics Inc. Announces Official Entry into the Ocular Market at ASCRS with the Launch of OptiCover™The First Shelf-Stable Lyophilized Amniotic Graft Containing HC-HA/PTX3 Designed for Efficient Workflow for Patients with Mild-to-Moderate Dry Eye
Cellution Biologics Inc. Announces First Peer-Reviewed Publication Demonstrating Positive Outcomes for AmchoPlast™ in the Treatment of Chronic Diabetic Foot UlcersROSWELL, Ga., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellution Biologics, Inc., a leader in regenerative allograft solutions, proudly announces the publication of its first peer-reviewed clinical article, “Bridging the Wound Gap: Interim Results from Randomized Trials Evaluating Dehydrated Human Amnion-Intermediate Layer-Chorion Membrane for the Treatment of Non-healing Diabetic Foot Ulcers,” published in Cureus. This milestone marks a significant achievement for the company and reinforces its commitment to advancing evidence-based medicine.
Cellution Biologics Inc. Announces U.S. Launch of AmnioPlast 1 and AmnioPlast Double for Ocular Surface RepairROSWELL, Ga., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellution Biologics Inc., today announced the introduction of AmnioPlast 1™ (Dehydrated Monolayered Human Amnion Membrane Allograft) and AmnioPlast Double™ (Dehydrated, Dual-Layer Amnion Membrane Allograft), intended for use as a cover or barrier applied to the ocular surface following repair or reconstruction procedures of ocular disease and/or abnormalities.
